An oligonucleotide containing a blocker, relating to the field of target sequence hybridization capture and the design and synthesis of universal blocking oligonucleotides. Applying an oligonucleotide that has a blocking function or a combination thereof not only has a good blocking effect on an linker sequence during the capture of a target sequence in a single sample, but also reduces non-specific capture and improves the capture efficiency. In particular, the oligonucleotide may effectively block linker sequences at both ends of a target sequence in a plurality of samples and improve the target sequence capture efficiency.

An oligonucleotide containing a blocker, relating to the field of target sequence hybridization capture and the design and synthesis of universal blocking oligonucleotides. Applying an oligonucleotide that has a blocking function or a combination thereof not only has a good blocking effect on an linker sequence during the capture of a target sequence in a single sample, but also reduces non-specific capture and improves the capture efficiency. In particular, the oligonucleotide may effectively block linker sequences at both ends of a target sequence in a plurality of samples and improve the target sequence capture efficiency.

Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

A method of reversibly labeling a biomolecule including providing a linker molecule (11) having a first functional group (LG) with a reactive center, a second functional group (FG) with a reactive center, and a cleavable, e.g. hydrolyzable, moiety (A-B-C). The method further includes forming a covalent bond between the biomolecule (10) and the reactive center of the first functional group (LG), forming a covalent bond between a first label (L1) and the reactive center of the second functional group (FG), cleaving the cleavable moiety (A-B-C), e.g. hydrolyzing the hydrolyzable moiety, of the linker molecule (11) to remove the first label (L1) and to form a third functional group (W) with a reactive center, and forming a covalent bond between a further molecule and the reactive center of the third functional group (W) to reform the cleavable moiety, e.g. hydrolyzable moiety (A-B-C).

Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

A method of separating a target double-stranded nucleic acid molecule from a sample including the target double-stranded nucleic acid molecule and a non-target double-stranded nucleic acid molecule, including (1) mixing the sample, a pyrrole-imidazole-containing polyamide (first PI polyamide) modified with a first linker molecule and capable of specifically binding to a sequence of the target double-stranded nucleic acid molecule, and a carrier a modified with a first ligand capable of specifically binding and/or adsorbing to the first linker molecule such that a mixed solution is produced, (2) forming a complex A by binding the carrier a to the first PI polyamide with which the target double-stranded nucleic acid molecule is bound in the mixed solution, and (3) separating the complex A from the mixed solution.

A method of separating a target double-stranded nucleic acid molecule from a sample including the target double-stranded nucleic acid molecule and a non-target double-stranded nucleic acid molecule, including (1) mixing the sample, a pyrrole-imidazole-containing polyamide (first PI polyamide) modified with a first linker molecule and capable of specifically binding to a sequence of the target double-stranded nucleic acid molecule, and a carrier a modified with a first ligand capable of specifically binding and/or adsorbing to the first linker molecule such that a mixed solution is produced, (2) forming a complex A by binding the carrier a to the first PI polyamide with which the target double-stranded nucleic acid molecule is bound in the mixed solution, and (3) separating the complex A from the mixed solution.

The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.

The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.